Abstract:The dual c-Met/vascular endothelial growth factor receptor 2 (VEGFR-2) TK inhibition is a good strategy to overcome therapeutic resistance to small molecules VEGFR-2 inhibitors. In this study, we designed 3-substituted quinazoline-2,4(1 H ,3 H )-dione derivatives as dual c-Met/VEGFR-2 TK inhibitors. We introduced new synthetic methods for reported derivatives of 3-substituted quinazoline-2,4(1 H ,3 H )-dione 2a – g , in addition to the preparation of some new derivatives namely, 3 and 4a – j . Three compounds namely, 2c , 4b , and 4e showed substantial amount of inhibition for both c-Met and VEGFR-2 TK (IC 50 range 0.052–0.084 μM). Both compounds 4b , 4e showed HB with highly conserved residue Asp1222 in the HB region of c-Met TK. For VEGFR-2 TK, compound 4b showed HB with a highly conserved residue Asp1046 in the HB region. Compound 4e showed HB with Glu885 and Asp1046. Moreover, in silico prediction of pharmacokinetic and physicochemical parameters of target compounds was carried out using SwissADME website. The quinazoline-2,4(1 H ,3 H )-dione derivatives are promising antiproliferative candidates that require further optimisation. New 3-substituted quinazoline-2,4(1 H ,3 H )-dione derivatives were synthesised and characterised. Compounds 4b and 4e showed higher cytotoxic activity than cabozantinib against HCT-116 colorectal cell lines. Both compounds 4b and 4e showed less toxicity to WI38 normal cell line compared to HCT 116 colon cancer cell line. Compound 4b was superior to cabozantinib in VEGFR-2 inhibition while compound 2c was equipotent to cabozantinib. Compounds 4b and 4e showed remarkable c-Met inhibitory activity. Compounds 4b and 4e arrested cell cycle and induced significant levels of apoptosis. In silico ADME prediction revealed high oral bioavailability and enhanced water solubility of target compounds as compared to cabozantinib. Target compounds interacted with both c-Met and VEGFR-2 active site in similar way to cabozantinib.

Design and Synthesis of Novel Benzo[D]Oxazol-2(3h)-One Derivatives Bearing 7-Substituted-4-enthoxyquinoline Moieties As C-Met Kinase Inhibitors

Design, Synthesis and Biological Evaluation of C-Met Kinase Inhibitors Bearing 2-Oxo-1,2-dihydroquinoline Scaffold

Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: synthesis and SAR study as tyrosine kinase c-Met inhibitors.

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors

Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors

Structure-based design, synthesis, and evaluation of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel c-Met inhibitors

Design and Optimization of Novel 4-(2-fluorophenoxy)quinoline Derivatives Bearing a Hydrazone Moiety As C-Met Kinase Inhibitors.

Structure-based Discovery of Novel 4-(2-fluorophenoxy)quinoline Derivatives As C-Met Inhibitors Using Isocyanide-Involved Multicomponent Reactions.

Enhancing the Cellular Anti-Proliferation Activity of Pyridazinones As C-Met Inhibitors Using Docking Analysis.

Synthesis And C-Met Kinase Inhibition Of 3,5-Disubstituted And 3,5,7-Trisubstituted Quinolines: Identification Of 3-(4-Acetylpiperazin-1-Y1)-5-(3-Nitrobenzylamino)-7-(Trifluoromethyl)Qui Noline As A Novel Anticancer Agent

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Design, synthesis and biological evaluation of thienopyridine derivatives as c-Met kinase inhibitors

Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity

Design, synthesis and evaluation of sulfonylurea-containing 4-phenoxyquinolines as highly selective c-Met kinase inhibitors.

Pyridazinone Derivatives Displaying Highly Potent and Selective Inhibitory Activities Against C-Met Tyrosine Kinase.

Synthesis and Antiproliferative Activity of 6,7-Disubstituted-4-phenoxyquinoline Derivatives Bearing the 2-Oxo-4-chloro-1,2-dihydroquinoline-3-carboxamide Moiety.

Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors

Design, Synthesis, Quantum Chemical Studies and Biological Activity Evaluation of Pyrazole-Benzimidazole Derivatives As Potent Aurora A/B Kinase Inhibitors.

Design, Synthesis and Biological Evaluation of Novel α‐Acyloxycarboxamide‐Based Derivatives as c‐Met Inhibitors

Design and biological evaluation of 3-substituted quinazoline-2,4(1H,3H)-dione derivatives as dual c-Met/VEGFR-2-TK inhibitors

Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Benzopyran and Phenylpyrazole Derivatives as Akt Inhibitors.